Mehrak Kiankarimi's Colleagues at QED Therapeutics
Mehrak Kiankarimi's Contact Details
HQ
650-231-4088
650-231-4088
Location
Oakland,California,United States
Oakland,California,United States
Company
QED Therapeutics
QED Therapeutics
Mehrak Kiankarimi's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Mehrak Kiankarimi
Mehrak Kiankarimi currently works for QED Therapeutics.
Mehrak Kiankarimi's role at QED Therapeutics is Vice President, Program Management.
Mehrak Kiankarimi's email address is ***@qedtx.com. To view Mehrak Kiankarimi's full email address, please signup to ConnectPlex.
Mehrak Kiankarimi works in the Research industry.
Mehrak Kiankarimi's colleagues at QED Therapeutics are Daniela Rogoff, Elizabeth Freas, Hao Wang, Francesca Avogadri-Connors, Hiywot Takkele, Sherry Markle, Sudesh Kamath and others.
Mehrak Kiankarimi's phone number is 650-231-4088